Official Title
Sonography for COVID-19 Vaccines Related Reactive Lymphadenopathy: A Retrospective Study
Brief Summary

This study aimed to provide vast clinical information to facilitate breast sonographicexamination for participants who underwent recent SARS-CoV-2 vaccination.Among different SARS-CoV-2 vaccines in the Asian Taiwanese population, reactive axillarylymphadenopathy was investigated through breast sonographic findings and clinical dataanalysis. The sample included participants with recent vaccinations by different brandsapproved in Taiwan.

Detailed Description

Study Design and Sample The retrospective study included female patients who underwent
breast sonography in the radiology department of Chi Mei Medical Center between July 2021
and March 2022. The patients' breast cancer history and COVID-19 vaccination history were
collected and analyzed.

Analysis of Breast Sonography Lymphadenopathy is defined as an enlarged lymph node with
cortical thickening >3 mm, either concentric or eccentric, with or without effacement of
fatty hilum, or in-creased non-hilar vascularity on color or power Doppler. The positive
axillary lymph node findings were correlated by confirming a link to SARS-CoV-2
vaccination history within 90 days in the ipsilateral arm.

Statistical Analysis All statistical analyses were performed using the R Stats package.
Descriptive summaries were reported as mean ± standard deviation for continuous variables
and percentages for categorical variables. For non-parametric variables, median with
interquartile range and Mann-Whitney U test were used. Statistical significance was set
at a p-value <0.05.

Completed
Reactive Axillary Lymphadenopathy for SARS-CoV-2 Vaccines in the Asian Taiwanese Population

Biological: the AstraZeneca ChAdOx1 (AZ) vaccine, Moderna mRNA-1273 (Moderna) vaccine, and Pfizer-BioNTech BNT162b2 (BNT) vaccine.

record the condition of vaccination

Eligibility Criteria

Inclusion Criteria:

- female patients receiving breast sonography

Exclusion Criteria:

- receive Covid 19 vaccine other than AZ, BNT, Moderna

- Ongoing primary breast malignancy

- History of malignancy other than primary breast malignancy

Eligibility Gender
Female
Eligibility Age
Minimum: 20 Years ~ Maximum: 80 Years
Countries
Taiwan
Locations

ChiMei Medical Center
Tainan City 1668355, Taiwan

Pin Chi Huang, Study Chair
ChiMei Medical Center, Taiwan, R.O.C.

Chimei Medical Center
NCT Number
Keywords
Breast Neoplasms
COVID-19 vaccine
lymphadenopathy
MeSH Terms
Breast Neoplasms
Lymphadenopathy
Vaccines